Literature DB >> 6239899

Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.

B Karpovsky, J A Titus, D A Stephany, D M Segal.   

Abstract

Rabbit anti-2,4-dintrophenyl (DNP) antibodies or their F(ab')2 fragments were chemically cross-linked to the anti-mouse Fc gamma R monoclonal antibody 2.4G2 or to its Fab fragment. P388D1 cells were incubated with heteroaggregates between 2.4G2 and anti-DNP (anti-Fc gamma R X anti-DNP) and washed. The resulting cells lysed 2,4,6-trinitrophenyl chicken erythrocytes (TNP CRBC) in a hapten-specific manner. The lysis was inhibited by free hapten but was resistant to inhibition by immune complexes. Other cells coated with antibody heteroaggregates also mediated lysis of TNP-modified target cells. For example, mouse resident peritoneal exudate cells (PEC) lysed TNP CRBC and bacillus Calmette-Guérin-activated PEC lysed both TNP CRBC and TNP tumor targets. Human neutrophils, when incubated with heteroaggregates containing the anti-human neutrophil Fc gamma R antibody 3G8 and anti-DNP also lysed TNP CRBC and TNP-modified tumor cells. To test whether linkage to Fc gamma R was required for lysis, F(ab')2 fragments from the anti-KdDd monoclonal antibody 34-1-2 were cross-linked to anti-DNP F(ab')2 fragments. P388D1 cells (which express Kd and Dd) were then incubated with these heteroaggregates and washed, and their abilities to form conjugates and lyse TNP CRBC were compared with those of P388D1 cells treated with anti-Fc gamma R X anti-DNP. In both cases, P388D1 cells formed conjugates. However, only the cells treated with anti-Fc gamma R X anti-DNP mediated lysis to a significant extent. We conclude that heteroaggregates containing anti-Fc gamma R and anti-target cell antibodies can be used to create potent effector cells against red cell and tumor targets and that bridging of effectors with target cells directly to Fc gamma R on effector cells is required for lysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6239899      PMCID: PMC2187539          DOI: 10.1084/jem.160.6.1686

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  Identification of macrophage-like characteristics in a cultured murine tumor line.

Authors:  H S Koren; B S Handwerger; J R Wunderlich
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

2.  A class of specific cytotoxic cells demonstrated in vitro by arming with antigen-antibody complexes.

Authors:  A H Greenberg; L Shen
Journal:  Nat New Biol       Date:  1973-10-31

3.  Competition for receptors for immunoglobulin on cytotoxic lymphocytes.

Authors:  I C MacLennan
Journal:  Clin Exp Immunol       Date:  1972-02       Impact factor: 4.330

4.  Cytotoxicity of human lymphocytes induced by rabbit antibodies to chicken erythrocytes. Inhibition by normal IgG and by human myeloma proteins of different IgG subclasses.

Authors:  A Larsson; P Perlmann; J B Natvig
Journal:  Immunology       Date:  1973-10       Impact factor: 7.397

5.  Inhibition of antibody-dependent human lymphocyte-mediated cytotoxicity by immunoglobulin classes, IgG subclasses, and IgG fragments.

Authors:  F Wisloff; T E Michaelsen; S S Froland
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

6.  Contactual lysis of antibody-coated chicken erythrocytes by purified lymphocytes.

Authors:  P Perlmann; H Perlmann
Journal:  Cell Immunol       Date:  1970-09       Impact factor: 4.868

Review 7.  The role of non-immune IgG in controlling IgG-mediated effector functions.

Authors:  D M Segal; S K Dower; J A Titus
Journal:  Mol Immunol       Date:  1983-11       Impact factor: 4.407

8.  The measurement of specific cell: cell interactions by dual-parameter flow cytometry.

Authors:  D M Segal; D A Stephany
Journal:  Cytometry       Date:  1984-03

9.  Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

Authors:  G Schulz; T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

10.  Trinitrophenyl modification of H-2k and H-2b spleen cells results in enhanced serological detection of Kk-like determinants.

Authors:  R B Levy; S K Dower; G M Shearer; D M Segal
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more
  33 in total

1.  Bispecific anti-human red blood Rhesus-D antigen x anti Fc gamma RI targeted antibody-dependent cell-mediated cytotoxicity and phagocytosis by mononuclear leucocytes.

Authors:  E X Deramoudt; C Gilard; N Lepine; J M Alonso; J L Romet-Lemonne
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

2.  Targeting of T-B interaction using heteroconjugate antibody.

Authors:  J L Davignon; M Vallin-Davignon; P L Cohen; R A Eisenberg
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

3.  Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.

Authors:  M S Chappel; D E Isenman; M Everett; Y Y Xu; K J Dorrington; M H Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

4.  Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment.

Authors:  R P Taylor; W M Sutherland; C J Reist; D J Webb; E L Wright; R H Labuguen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 5.  Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.

Authors:  Gert Riethmüller
Journal:  Cancer Immun       Date:  2012-05-01

Review 6.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Authors:  Patrick Chames; Daniel Baty
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 7.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

8.  Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1.

Authors:  P D Foglesong; M A Winkler; J O Price; G D Marshall; S H Reagh; D A Bush; K S Hixson; W H West
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 9.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

10.  Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma.

Authors:  A Eisenthal; S A Rosenberg
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.